Purpose: Ifosfamide plus mesna have been used recently in a high-dose regimen that allows this chemotherapy to be given to outpatients with less toxicity over 14 days using a portable pump. However, there is a need for published stability information. The aim of this study was to investigate the physicochemical stability of ifosfamide with mesna in normal saline at room temperature over a prolonged period of 14 days.
Methods: Infusion solutions of 1:1 ifosfamide and mesna at final concentrations of 10, 20 and 30 mg/mL were prepared with 0.9% sodium chloride in PVC bags. Solutions were stored at room temperature. Concentrations of ifosfamide and mesna were measured at 0 and 1, 3, 7 and 14 days using a stability-indicating reversed phase high-performance liquid chromatography (HPLC) assay with ultraviolet detection.
Results: Ifosfamide and mesna were both physicochemically stable (>94%) for 14 days in all tested infusion solutions (10, 20 and 30 mg/mL).
Conclusions: Our stability data indicate that ifosfamide and mesna (1:1) combination can be administered as a prolonged continuous infusion with portable pump in an outpatient setting without replacement of the infusion bag. We suggest 20 mg/mL as a reasonable concentration for infusion rates of about 2-4 cc/hr over prolonged periods of time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1078155213478284 | DOI Listing |
Cureus
December 2024
Internal Medicine/Nephrology, Riverside Health System, Yonkers, USA.
We conducted a large-scale disproportionality analysis of the urotoxicity of cyclophosphamide (CYC) and the related drug ifosfamide (IFO) using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, with data ranging from Q4 2012 to Q2 2024. We compared the reporting odds ratio (ROR) of various urotoxicity manifestations of CYC and IFO across patient populations being treated for antineoplastic, immunosuppressive, and transplantation indications. When a wide range of urotoxicity manifestations was aggregated, we found that transplant patients had an increased relative susceptibility to CYC urotoxicity.
View Article and Find Full Text PDFCureus
November 2024
Pathology and Laboratory Medicine, University of California Davis Health System, Sacramento, USA.
We present a case of a 36-year-old male found to have a nonseminomatous germ cell tumor (NSGCT) with alpha-fetoprotein levels (AFP) of 737.9 ng/mL and beta-human chorionic gonadotropin (β-HCG) of 692 IU/mL. Pathology analysis after left orchiectomy showed a mixed germ cell tumor with 20% embryonal carcinoma, 20% yolk sac tumor, and 60% teratoma.
View Article and Find Full Text PDFCase Rep Oncol
November 2024
Department of Internal Medicine, Baylor Scott & White Medical Center, Temple, TX, USA.
Cancer Med
September 2024
Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Background: The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.
Aims: The study was to investigate safety and activity of neoadjuvant chemotherapy with camrelizumab (a humanized antibody against PD-1) in patients with resectable OS.
Respir Med Case Rep
June 2024
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Synovial sarcoma is a rare and aggressive tumor that primarily affects soft tissues, including the mediastinum, and predominantly affects younger adults. A 23-year-old male patient with mediastinal synovial sarcoma underwent debulking surgery and received 3 cycles of doxorubicin, ifosfamide, and mesna chemotherapy. Mediastinal synovial sarcoma presents diagnostic challenges and poor prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!